Pembrolizumab (Keytruda) | Zendy

Reimbursement Team | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pembrolizumab (Keytruda)

Author(s) -

Reimbursement Team

Publication year - 2021

Publication title -

canadian journal of health technologies

Language(s) - English

Resource type - Journals

ISSN - 2563-6596

DOI - 10.51731/cjht.2021.158

Subject(s) - reimbursement , pembrolizumab , microsatellite instability , medicine , drug , colorectal cancer , family medicine , cancer , political science , pharmacology , health care , allele , biochemistry , chemistry , immunotherapy , law , microsatellite , gene

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses pembrolizumab (Keytruda) 200 mg administered intravenouslyIndication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research